Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/211921
Emerging Agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
ntroduction: Chagas disease treatment relies on the lengthy administration of benznidazole and/or nifurtimox, which have frequent toxicity associated. The disease, caused by the parasite Trypanosoma cruzi, is mostly diagnosed at its chronic phase when life-threatening symptomatology manifest in approximately 30% of those infected. Considering that both available drugs have variable efficacy by then, and there are over 6 million people infected, there is a pressing need to find safer, more efficacious drugs. Areas covered: We provide an updated view of the path to achieve the aforementioned goal. From state-of-the-art in vitro and in vivo assays based on genetically engineered parasites that have allowed high throughput screenings of large chemical collections, to the unfulfilled requirement of having treatment-response biomarkers for the clinical evaluation of drugs. In between, we describe the most promising pre-clinical hits and the landscape of clinical trials with new drugs or new regimens of existing ones. Moreover, the use of monkey models to reduce the pre-clinical to clinical attrition rate is discussed. Expert opinion: In addition to the necessary research on new drugs and much awaited biomarkers of treatment efficacy, a key step will be to generalize access to diagnosis and treatment and maximize efforts to impede transmission.
Matèries
Matèries (anglès)
Citació
Citació
MARTINEZ-PEINADO, Nieves, CORTES SERRA, Núria, LOSADA GALVÁN, Irene, ALONSO VEGA, Cristina, URBINA, Julio a., RODRÍGUEZ, Ana, VANDEBERG, John l., PINAZO, Maria-jesus, GASCÓN I BRUSTENGA, Joaquim, ALONSO PADILLA, Julio. Emerging Agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?. _Expert Opinion on Investigational Drugs_. 2020. Vol. 29, núm. 9, pàgs. 947-959. [consulta: 25 de febrer de 2026]. ISSN: 1354-3784. [Disponible a: https://hdl.handle.net/2445/211921]